Evaluation of dose and outcomes for pediatric vilazodone ingestions
| Autor: | Christopher E. Gaw, Thiphalak Chounthirath, Henry A. Spiller, Gary A. Smith, Jason L. Russell |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Poison Control Centers Adolescent Serotonin reuptake inhibitor Vilazodone Hydrochloride Poison control Toxicology 03 medical and health sciences chemistry.chemical_compound Patient Admission 0302 clinical medicine Vilazodone medicine Retrospective analysis Humans Ingestion 030212 general & internal medicine Clinical efficacy Child Depression (differential diagnoses) Retrospective Studies Dose-Response Relationship Drug business.industry digestive oral and skin physiology Age Factors Infant 030208 emergency & critical care medicine General Medicine United States Treatment Outcome chemistry Child Preschool Anesthesia Female business Selective Serotonin Reuptake Inhibitors |
| Zdroj: | Clinical Toxicology. 56:113-119 |
| ISSN: | 1556-9519 1556-3650 |
| Popis: | Selective serotonin reuptake inhibitor (SSRI) exposures among children younger than 6 years of age are generally well tolerated. Vilazodone is an SSRI with partial agonism at the 5-HTA retrospective analysis of single-substance exposures associated with vilazodone among children younger than 6 years of age from 2011 through 2016 was conducted using data from the National Poison Data System.During 2011-2016, 753 vilazodone ingestions among children6 years old were reported to US poison control centers. A near majority (49.0%, n = 369) experienced one or more clinical effects. The dose ingested was reported for 596 children (79%). The median dose associated with major effects was 50.0mg (Mean: 106.0) compared with 40.0mg (Mean 81.1) for moderate effects. Half (50.0%) of children with a major effect and 54.0% with a moderate effect ingested ≤40 mg of vilazodone. As the dose of vilazodone ingested increased, the proportions of exposures admitted to a healthcare facility (HCF) (p .001) and with serious outcomes (p .001) both increased. Children ≤2 years had higher proportions of HCF admission (33.8% vs 23.1%) and serious outcomes (27.0% vs 17.7%) than children 3-5 years of age. Clinical effects, such as coma, seizures, ataxia, and hallucinations/delusions, were observed among children ingesting doses of vilazodone as low as 10 mg.Exposure to vilazodone poses a unique and potentially serious threat to children6 years of age. Children in this age group who are exposed to vilazodone should be evaluated promptly in a clinical setting. Off-label use of vilazodone in children under 6 years should be discouraged until further research is conducted regarding its safety in this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|